Rep. Norm Thurston — Voting Record

Utah House District 62 · complete roll-call record from le.utah.gov
← All votes

Bill

Pharmacy Practice Amendments
Number
S.B. 261 (2026GS)
Sponsor
Sen. Vickers, Evan J.
Final action
Governor Signed 3/18/2026
Outcome
Became law — signed by Gov. Spencer J. Cox

Summary

This bill amends provisions related to the practice of pharmacy.

What it does

  • This bill:
  • amends the definition of a collaborative pharmacy practice agreement to conform to other provisions of code regarding a pharmacist's role under a collaborative pharmacy practice agreement;
  • adds vaccines and epinephrine to the list of prescription drugs that a pharmacist may prescribe;
  • permits online sales of pseudoephedrine under certain circumstances;
  • requires the Division of Professional Licensing, in collaboration with the Board of Pharmacy, to approve and implement an electronic tracking system to monitor the sale of pseudoephedrine under certain circumstances;
  • defines terms; and
  • makes technical and conforming changes.

Every vote on this bill

2026-02-12Senate Comm - Substitute Recommendation
Senate Business and Labor Committee
5-0-3not eligible / no record
2026-02-12Senate Comm - Favorable Recommendation
Senate Business and Labor Committee
6-0-2not eligible / no record
2026-03-03House Comm - Favorable Recommendation
House Health and Human Services Committee
10-0-4not eligible / no record
2026-02-24Senate/ passed 2nd reading
Senate 3rd Reading Calendar
24-0-5not eligible / no record
2026-02-25Senate/ passed 3rd reading
Clerk of the House
22-0-7not eligible / no record
2026-03-06House/ passed 3rd reading
House Speaker
63-1-11YEA

Bill text

enrolled version · official source
20
58-17b-102
58-17b-612
58-17b-627
58-37c-3
58-37c-22
0
Pharmacy Practice Amendments
2026 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Evan J. Vickers
House Sponsor: Steve Eliason
LONG TITLE
General Description:
This bill amends provisions related to the practice of pharmacy.
Highlighted Provisions:
This bill:
amends the definition of a collaborative pharmacy practice agreement to conform to other 
provisions of code regarding a pharmacist's role under a collaborative pharmacy practice 
agreement;
adds vaccines and epinephrine to the list of prescription drugs that a pharmacist may 
prescribe; 
permits online sales of pseudoephedrine under certain circumstances;
requires the Division of Professional Licensing, in collaboration with the Board of 
Pharmacy, to approve and implement an electronic tracking system to monitor the sale 
of pseudoephedrine under certain circumstances; 
defines terms; and
makes technical and conforming changes.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
58-17b-102
, as last amended by Laws of Utah 2025, Chapter 486
58-17b-612
, as last amended by Laws of Utah 2019, Chapter 343
58-17b-627
, as last amended by Laws of Utah 2025, Chapter 513
58-37c-3
, as last amended by Laws of Utah 2024, Chapter 113
ENACTS:
58-37c-22
, Utah Code Annotated 1953
Be it enacted by the Legislature of the state of Utah:
Section 1. Section 
58-17b-102
 is amended to read:
58-17b-102
. Definitions.
In addition to the definitions in Section 
58-1-102
, as used in this chapter:
(1)
"Administering" means:
(a)
the direct application of a prescription drug or device, whether by injection, 
inhalation, ingestion, or by any other means, to the body of a human patient or 
research subject by another person; or
(b)
the placement by a veterinarian with the owner or caretaker of an animal or group of 
animals of a prescription drug for the purpose of injection, inhalation, ingestion, or 
any other means directed to the body of the animal by the owner or caretaker in 
accordance with written or verbal directions of the veterinarian.
(2)
"Adulterated drug or device" means a drug or device considered adulterated under 21 
U.S.C. Sec. 351 (2003).
(3)
(a)
"Analytical laboratory" means a facility in possession of prescription drugs for the 
purpose of analysis.
(b)
"Analytical laboratory" does not include a laboratory possessing prescription drugs 
used as standards and controls in performing drug monitoring or drug screening 
analysis if the prescription drugs are prediluted in a human or animal body fluid, 
human or animal body fluid components, organic solvents, or inorganic buffers at a 
concentration not exceeding one milligram per milliliter when labeled or otherwise 
designated as being for in vitro diagnostic use.
(4)
"Animal euthanasia agency" means an agency performing euthanasia on animals by the 
use of prescription drugs.
(5)
"Automated pharmacy systems" includes mechanical systems which perform operations 
or activities, other than compounding or administration, relative to the storage, 
packaging, dispensing, or distribution of medications, and which collect, control, and 
maintain all transaction information.
(6)
"Beyond use date" means the date determined by a pharmacist and placed on a 
prescription label at the time of dispensing that indicates to the patient or caregiver a 
time beyond which the contents of the prescription are not recommended to be used.
(7)
"Board of pharmacy" or "board" means the Utah State Board of Pharmacy created in 
Section 
58-17b-201
.
(8)
"Branch pharmacy" means a pharmacy or other facility in a rural or medically 
underserved area, used for the storage and dispensing of prescription drugs, which is 
dependent upon, stocked by, and supervised by a pharmacist in another licensed 
pharmacy designated and approved by the division as the parent pharmacy.
(9)
"Centralized prescription processing" means the processing by a pharmacy of a request 
from another pharmacy to fill or refill a prescription drug order or to perform processing 
functions such as dispensing, drug utilization review, claims adjudication, refill 
authorizations, and therapeutic interventions.
(10)
"Class A pharmacy" means a pharmacy located in Utah that is authorized as a retail 
pharmacy to compound or dispense a drug or dispense a device to the public under a 
prescription order.
(11)
"Class B pharmacy":
(a)
means a pharmacy located in Utah:
(i)
that is authorized to provide pharmaceutical care for patients in an institutional 
setting; and
(ii)
whose primary purpose is to provide a physical environment for patients to obtain 
health care services; and
(b)
(i)
includes closed-door, hospital, clinic, nuclear, and branch pharmacies; and
(ii)
pharmaceutical administration and sterile product preparation facilities.
(12)
"Class C pharmacy" means a pharmacy that engages in the manufacture, production, 
wholesale, or distribution of drugs or devices in Utah.
(13)
"Class D pharmacy" means a nonresident pharmacy.
(14)
"Class E pharmacy" means all other pharmacies.
(15)
(a)
"Closed-door pharmacy" means a pharmacy that:
(i)
provides pharmaceutical care to a defined and exclusive group of patients who 
have access to the services of the pharmacy because they are treated by or have an 
affiliation with a specific entity, including a health maintenance organization or an 
infusion company; or
(ii)
engages exclusively in the practice of telepharmacy and does not serve walk-in 
retail customers.
(b)
"Closed-door pharmacy" does not include a hospital pharmacy, a retailer of goods to 
the general public, or the office of a practitioner.
(16)
"Collaborative pharmacy practice" means a practice of pharmacy whereby one or more 
pharmacists have jointly agreed, on a voluntary basis, to work in conjunction with one or 
more practitioners under protocol whereby the pharmacist may perform certain 
pharmaceutical care functions authorized by the practitioner or practitioners under 
certain specified conditions or limitations.
(17)
"Collaborative pharmacy practice agreement" means a written and signed agreement 
between one or more pharmacists and one or more practitioners that provides for 
collaborative pharmacy practice for the purpose of drug therapy management of patients
, 
initiating therapy,
 and prevention of disease of human subjects.
(18)
(a)
"Compounding" means the preparation, mixing, assembling, packaging, or 
labeling of a limited quantity drug, sterile product, or device:
(i)
as the result of a practitioner's prescription order or initiative based on the 
practitioner, patient, or pharmacist relationship in the course of professional 
practice;
(ii)
for the purpose of, or as an incident to, research, teaching, or chemical analysis 
and not for sale or dispensing; or
(iii)
in anticipation of prescription drug orders based on routine, regularly observed 
prescribing patterns.
(b)
"Compounding" does not include:
(i)
the preparation of prescription drugs by a pharmacist or pharmacy intern for sale 
to another pharmacist or pharmaceutical facility;
(ii)
the preparation by a pharmacist or pharmacy intern of any prescription drug in a 
dosage form which is regularly and commonly available from a manufacturer in 
quantities and strengths prescribed by a practitioner; or
(iii)
the preparation of a prescription drug, sterile product, or device which has been 
withdrawn from the market for safety reasons.
(19)
"Confidential information" has the same meaning as "protected health information" 
under the Standards for Privacy of Individually Identifiable Health Information, 45 
C.F.R. Parts 160 and 164.
(20)
"Controlled substance" means the same as that term is defined in Section 
58-37-2
.
(21)
"Dietary supplement" has the same meaning as Public Law Title 103, Chapter 417, 
Sec. 3a(ff) which is incorporated by reference.
(22)
"Dispense" means the interpretation, evaluation, and implementation of a prescription 
drug order or device or nonprescription drug or device under a lawful order of a 
practitioner in a suitable container appropriately labeled for subsequent administration to 
or use by a patient, research subject, or an animal.
(23)
"Dispensing medical practitioner" means an individual who is:
(a)
currently licensed as:
(i)
a physician and surgeon under Chapter 67, Utah Medical Practice Act;
(ii)
an osteopathic physician and surgeon under Chapter 68, Utah Osteopathic 
Medical Practice Act;
(iii)
a physician assistant under Chapter 70a, Utah Physician Assistant Act;
(iv)
a nurse practitioner under Chapter 31b, Nurse Practice Act; or
(v)
an optometrist under Chapter 16a, Utah Optometry Practice Act, if the 
optometrist is acting within the scope of practice for an optometrist; and
(b)
licensed by the division under the Pharmacy Practice Act to engage in the practice of 
a dispensing medical practitioner.
(24)
"Dispensing medical practitioner clinic pharmacy" means a closed-door pharmacy 
located within a licensed dispensing medical practitioner's place of practice.
(25)
"Distribute" means to deliver a drug or device other than by administering or 
dispensing.
(26)
(a)
"Drug" means:
(i)
a substance recognized in the official United States Pharmacopoeia, official 
Homeopathic Pharmacopoeia of the United States, or official National Formulary, 
or any supplement to any of them, intended for use in the diagnosis, cure, 
mitigation, treatment, or prevention of disease in humans or animals;
(ii)
a substance that is required by any applicable federal or state law or rule to be 
dispensed by prescription only or is restricted to administration by practitioners 
only;
(iii)
a substance other than food intended to affect the structure or any function of the 
body of humans or other animals; and
(iv)
substances intended for use as a component of any substance specified in 
Subsections 
(26)(a)(i)
 through 
(iii)
.
(b)
"Drug" does not include dietary supplements.
(27)
"Drug regimen review" includes the following activities:
(a)
evaluation of the prescription drug order and patient record for:
(i)
known allergies;
(ii)
rational therapy-contraindications;
(iii)
reasonable dose and route of administration; and
(iv)
reasonable directions for use;
(b)
evaluation of the prescription drug order and patient record for duplication of therapy;
(c)
evaluation of the prescription drug order and patient record for the following 
interactions:
(i)
drug-drug;
(ii)
drug-food;
(iii)
drug-disease; and
(iv)
adverse drug reactions; and
(d)
evaluation of the prescription drug order and patient record for proper utilization, 
including over- or under-utilization, and optimum therapeutic outcomes.
(28)
"Drug sample" means a prescription drug packaged in small quantities consistent with 
limited dosage therapy of the particular drug, which is marked "sample", is not intended 
to be sold, and is intended to be provided to practitioners for the immediate needs of 
patients for trial purposes or to provide the drug to the patient until a prescription can be 
filled by the patient.
(29)
"Electronic signature" means a trusted, verifiable, and secure electronic sound, symbol, 
or process attached to or logically associated with a record and executed or adopted by a 
person with the intent to sign the record.
(30)
"Electronic transmission" means transmission of information in electronic form or the 
transmission of the exact visual image of a document by way of electronic equipment.
(31)
"Hospital pharmacy" means a pharmacy providing pharmaceutical care to inpatients of 
a general acute hospital or specialty hospital licensed by the Department of Health and 
Human Services under Title 26B, Chapter 2, Part 2, Health Care Facility Licensing and 
Inspection.
(32)
"Legend drug" has the same meaning as prescription drug.
(33)
"Licensed pharmacy technician" means an individual licensed with the division, that 
may, under the supervision of a pharmacist, perform the activities involved in the 
technician practice of pharmacy.
(34)
"Manufacturer" means a person or business physically located in Utah licensed to be 
engaged in the manufacturing of drugs or devices.
(35)
(a)
"Manufacturing" means:
(i)
the production, preparation, propagation, conversion, or processing of a drug or 
device, either directly or indirectly, by extraction from substances of natural origin 
or independently by means of chemical or biological synthesis, or by a 
combination of extraction and chemical synthesis, and includes any packaging or 
repackaging of the substance or labeling or relabeling of its container; and
(ii)
the promotion and marketing of such drugs or devices.
(b)
"Manufacturing" includes the preparation and promotion of commercially available 
products from bulk compounds for resale by pharmacies, practitioners, or other 
persons.
(c)
"Manufacturing" does not include the preparation or compounding of a drug by a 
pharmacist, pharmacy intern, or practitioner for that individual's own use or the 
preparation, compounding, packaging, labeling of a drug, or incident to research, 
teaching, or chemical analysis.
(36)
"Medical order" means a lawful order of a practitioner which may include a 
prescription drug order.
(37)
"Medication profile" or "profile" means a record system maintained as to drugs or 
devices prescribed for a pharmacy patient to enable a pharmacist or pharmacy intern to 
analyze the profile to provide pharmaceutical care.
(38)
"Misbranded drug or device" means a drug or device considered misbranded under 21 
U.S.C. Sec. 352 (2003).
(39)
(a)
"Nonprescription drug" means a drug which:
(i)
may be sold without a prescription; and
(ii)
is labeled for use by the consumer in accordance with federal law.
(b)
"Nonprescription drug" includes homeopathic remedies.
(40)
"Nonresident pharmacy" means a pharmacy located outside of Utah that sells to a 
person in Utah.
(41)
"Nuclear pharmacy" means a pharmacy providing radio-pharmaceutical service.
(42)
"Out-of-state mail service pharmacy" means a pharmaceutical facility located outside 
the state that is licensed and in good standing in another state, that:
(a)
ships, mails, or delivers by any lawful means a dispensed legend drug to a patient in 
this state pursuant to a lawfully issued prescription;
(b)
provides information to a patient in this state on drugs or devices which may include, 
but is not limited to, advice relating to therapeutic values, potential hazards, and uses; 
or
(c)
counsels pharmacy patients residing in this state concerning adverse and therapeutic 
effects of drugs.
(43)
"Patient counseling" means the written and oral communication by the pharmacist or 
pharmacy intern of information, to the patient or caregiver, in order to ensure proper use 
of drugs, devices, and dietary supplements.
(44)
"Pharmaceutical administration facility" means a facility, agency, or institution in 
which:
(a)
prescription drugs or devices are held, stored, or are otherwise under the control of 
the facility or agency for administration to patients of that facility or agency;
(b)
prescription drugs are dispensed to the facility or agency by a licensed pharmacist or 
pharmacy intern with whom the facility has established a prescription drug 
supervising relationship under which the pharmacist or pharmacy intern provides 
counseling to the facility or agency staff as required, and oversees drug control, 
accounting, and destruction; and
(c)
prescription drugs are professionally administered in accordance with the order of a 
practitioner by an employee or agent of the facility or agency.
(45)
(a)
"Pharmaceutical care" means carrying out the following in collaboration with a 
prescribing practitioner, and in accordance with division rule:
(i)
designing, implementing, and monitoring a therapeutic drug plan intended to 
achieve favorable outcomes related to a specific patient for the purpose of curing 
or preventing the patient's disease;
(ii)
eliminating or reducing a patient's symptoms; or
(iii)
arresting or slowing a disease process.
(b)
"Pharmaceutical care" does not include prescribing of drugs without consent of a 
prescribing practitioner.
(46)
"Pharmaceutical facility" means a business engaged in the dispensing, delivering, 
distributing, manufacturing, or wholesaling of prescription drugs or devices within or 
into this state.
(47)
(a)
"Pharmaceutical wholesaler or distributor" means a pharmaceutical facility 
engaged in the business of wholesale vending or selling of a prescription drug or 
device to other than a consumer or user of the prescription drug or device that the 
pharmaceutical facility has not produced, manufactured, compounded, or dispensed.
(b)
"Pharmaceutical wholesaler or distributor" does not include a pharmaceutical facility 
carrying out the following business activities:
(i)
intracompany sales;
(ii)
the sale, purchase, or trade of a prescription drug or device, or an offer to sell, 
purchase, or trade a prescription drug or device, if the activity is carried out 
between one or more of the following entities under common ownership or 
common administrative control, as defined by division rule:
(A)
hospitals;
(B)
pharmacies;
(C)
chain pharmacy warehouses, as defined by division rule; or
(D)
other health care entities, as defined by division rule;
(iii)
the sale, purchase, or trade of a prescription drug or device, or an offer to sell, 
purchase, or trade a prescription drug or device, for emergency medical reasons, 
including supplying another pharmaceutical facility with a limited quantity of a 
drug, if:
(A)
the facility is unable to obtain the drug through a normal distribution channel 
in sufficient time to eliminate the risk of harm to a patient that would result 
from a delay in obtaining the drug; and
(B)
the quantity of the drug does not exceed an amount reasonably required for 
immediate dispensing to eliminate the risk of harm;
(iv)
the distribution of a prescription drug or device as a sample by representatives of 
a manufacturer; and
(v)
the distribution of prescription drugs, if:
(A)
the facility's total distribution-related sales of prescription drugs does not 
exceed 5% of the facility's total prescription drug sales; and
(B)
the distribution otherwise complies with 21 C.F.R. Sec. 1307.11.
(48)
"Pharmacist" means an individual licensed by this state to engage in the practice of 
pharmacy.
(49)
"Pharmacist-in-charge" means a pharmacist currently licensed in good standing who 
accepts responsibility for the operation of a pharmacy in conformance with all laws and 
rules pertinent to the practice of pharmacy and the distribution of drugs, and who is 
personally in full and actual charge of the pharmacy and all personnel.
(50)
"Pharmacist preceptor" means a licensed pharmacist in good standing with one or 
more years of licensed experience. The preceptor serves as a teacher, example of 
professional conduct, and supervisor of interns in the professional practice of pharmacy.
(51)
"Pharmacy" means any place where:
(a)
drugs are dispensed;
(b)
pharmaceutical care is provided;
(c)
drugs are processed or handled for eventual use by a patient; or
(d)
drugs are used for the purpose of analysis or research.
(52)
"Pharmacy benefits manager or coordinator" means a person or entity that provides a 
pharmacy benefits management service as defined in Section 
31A-46-102
 on behalf of a 
self-insured employer, insurance company, health maintenance organization, or other 
plan sponsor, as defined by rule.
(53)
"Pharmacy intern" means an individual licensed by this state to engage in practice as a 
pharmacy intern.
(54)
"Pharmacy manager" means:
(a)
a pharmacist-in-charge;
(b)
a licensed pharmacist designated by a licensed pharmacy to consult on the 
pharmacy's administration;
(c)
an individual who manages the facility in which a licensed pharmacy is located;
(d)
an individual who oversees the operations of a licensed pharmacy;
(e)
an immediate supervisor of an individual described in Subsections 
(54)(a)
 through 
(d)
; 
or
(f)
another operations or site manager of a licensed pharmacy.
(55)
"Pharmacy technician training program" means an approved technician training 
program providing education for pharmacy technicians.
(56)
(a)
"Practice as a dispensing medical practitioner" means the practice of pharmacy, 
specifically relating to the dispensing of a prescription drug in accordance with Part 
8, Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic 
Pharmacy, and division rule adopted after consultation with the Board of pharmacy 
and the governing boards of the practitioners described in Subsection 
(23)(a)
.
(b)
"Practice as a dispensing medical practitioner" does not include:
(i)
using a vending type of dispenser as defined by the division by administrative 
rule; or
(ii)
except as permitted by Section 
58-17b-805
, dispensing of a controlled substance 
as defined in Section 
58-37-2
.
(57)
"Practice as a licensed pharmacy technician" means engaging in practice as a 
pharmacy technician under the general supervision of a licensed pharmacist and in 
accordance with a scope of practice defined by division rule made in collaboration with 
the board.
(58)
"Practice of pharmacy" includes the following:
(a)
providing pharmaceutical care;
(b)
collaborative pharmacy practice in accordance with a collaborative pharmacy 
practice agreement;
(c)
compounding, packaging, labeling, dispensing, administering, and the coincident 
distribution of prescription drugs or devices, provided that the administration of a 
prescription drug or device is:
(i)
pursuant to a lawful order of a practitioner when one is required by law; and
(ii)
in accordance with written guidelines or protocols:
(A)
established by the licensed facility in which the prescription drug or device is 
to be administered on an inpatient basis; or
(B)
approved by the division, in collaboration with the board and, when 
appropriate, the Medical Licensing Board, created in Section 
58-67-201
, if the 
prescription drug or device is to be administered on an outpatient basis solely 
by a licensed pharmacist;
(d)
participating in drug utilization review;
(e)
ensuring proper and safe storage of drugs and devices;
(f)
maintaining records of drugs and devices in accordance with state and federal law 
and the standards and ethics of the profession;
(g)
providing information on drugs or devices, which may include advice relating to 
therapeutic values, potential hazards, and uses;
(h)
providing drug product equivalents;
(i)
supervising pharmacist's supportive personnel, pharmacy interns, and pharmacy 
technicians;
(j)
providing patient counseling, including adverse and therapeutic effects of drugs;
(k)
providing emergency refills as defined by rule;
(l)
telepharmacy;
(m)
formulary management intervention;
(n)
prescribing and dispensing a self-administered hormonal contraceptive in accordance 
with Title 26B, Chapter 4, Part 5, Treatment Access; and
(o)
issuing a prescription in accordance with Section 
58-17b-610.8
 or 
58-17b-627
.
(59)
"Practice of telepharmacy" means the practice of pharmacy through the use of 
telecommunications and information technologies.
(60)
"Practice of telepharmacy across state lines" means the practice of pharmacy through 
the use of telecommunications and information technologies that occurs when the 
patient is physically located within one jurisdiction and the pharmacist is located in 
another jurisdiction.
(61)
"Practitioner" means an individual currently licensed, registered, or otherwise 
authorized by the appropriate jurisdiction to prescribe and administer drugs in the course 
of professional practice.
(62)
"Prescribe" means to issue a prescription:
(a)
orally or in writing; or
(b)
by telephone, facsimile transmission, computer, or other electronic means of 
communication as defined by division rule.
(63)
"Prescription" means an order issued:
(a)
by a licensed practitioner in the course of that practitioner's professional practice or 
by collaborative pharmacy practice agreement; and
(b)
for a controlled substance or other prescription drug or device for use by a patient or 
an animal.
(64)
"Prescription device" means an instrument, apparatus, implement, machine, 
contrivance, implant, in vitro reagent, or other similar or related article, and any 
component part or accessory, which is required under federal or state law to be 
prescribed by a practitioner and dispensed by or through a person or entity licensed 
under this chapter or exempt from licensure under this chapter.
(65)
"Prescription drug" means a drug that is required by federal or state law or rule to be 
dispensed only by prescription or is restricted to administration only by practitioners.
(66)
"Repackage":
(a)
means changing the container, wrapper, or labeling to further the distribution of a 
prescription drug; and
(b)
does not include:
(i)
Subsection 
(66)(a)
 when completed by the pharmacist responsible for dispensing 
the product to a patient; or
(ii)
changing or altering a label as necessary for a dispensing practitioner under Part 
8, Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic 
Pharmacy, for dispensing a product to a patient.
(67)
"Research using pharmaceuticals" means research:
(a)
conducted in a research facility, as defined by division rule, that is associated with a 
university or college in the state accredited by the Northwest Commission on 
Colleges and Universities;
(b)
requiring the use of a controlled substance, prescription drug, or prescription device;
(c)
that uses the controlled substance, prescription drug, or prescription device in 
accordance with standard research protocols and techniques, including, if required, 
those approved by an institutional review committee; and
(d)
that includes any documentation required for the conduct of the research and the 
handling of the controlled substance, prescription drug, or prescription device.
(68)
"Retail pharmacy" means a pharmaceutical facility dispensing prescription drugs and 
devices to the general public.
(69)
(a)
"Self-administered hormonal contraceptive" means a self-administered hormonal 
contraceptive that is approved by the United States Food and Drug Administration to 
prevent pregnancy.
(b)
"Self-administered hormonal contraceptive" includes an oral hormonal contraceptive, 
a hormonal vaginal ring, and a hormonal contraceptive patch.
(c)
"Self-administered hormonal contraceptive" does not include any drug intended to 
induce an abortion, as that term is defined in Section 
76-7-301
.
(70)
"Self-audit" means an internal evaluation of a pharmacy to determine compliance with 
this chapter.
(71)
"Supervising pharmacist" means a pharmacist who is overseeing the operation of the 
pharmacy during a given day or shift.
(72)
"Supportive personnel" means unlicensed individuals who:
(a)
may assist a pharmacist, pharmacist preceptor, pharmacy intern, or licensed 
pharmacy technician in nonjudgmental duties not included in the definition of the 
practice of pharmacy, practice of a pharmacy intern, or practice of a licensed 
pharmacy technician, and as those duties may be further defined by division rule 
adopted in collaboration with the board; and
(b)
are supervised by a pharmacist in accordance with rules adopted by the division in 
collaboration with the board.
(73)
"Unlawful conduct" means the same as that term is defined in Sections 
58-1-501
 and 
58-17b-501
.
(74)
"Unprofessional conduct" means the same as that term is defined in Sections 
58-1-501
and 
58-17b-502
 and may be further defined by rule.
(75)
"Veterinary pharmaceutical facility" means a pharmaceutical facility that dispenses 
drugs intended for use by animals or for sale to veterinarians for the administration for 
animals.
(76)
"Written communication" means a physical document, or an electronic 
communication, by or from which the recipient may read or access the information 
intended to be communicated, including:
(a)
email;
(b)
text message; and
(c)
quick response (QR) code.
Section 2. Section 
58-17b-612
 is amended to read:
58-17b-612
. Supervision -- Pharmacist-in-charge.
(1)
(a)
Any pharmacy, except a wholesaler, distributor, out-of-state mail service 
pharmacy, or class E pharmacy, shall be under the general supervision of at least one 
pharmacist licensed to practice in Utah. One pharmacist licensed in Utah shall be 
designated as the pharmacist-in-charge, whose responsibility it is to oversee the 
operation of the pharmacy.
(b)
Notwithstanding Subsection 
58-17b-102(70)
58-17b-102(71)
, a supervising 
pharmacist does not have to be in the pharmacy or care facility but shall be available 
via a telepharmacy system for immediate contact with the supervised pharmacy 
technician or pharmacy intern if:
(i)
the pharmacy is located in an area of need as defined by the division, in 
consultation with the board, by rule made in accordance with 
Title 63G, Chapter 
3, Utah Administrative Rulemaking Act
;
(ii)
the supervising pharmacist described in Subsection 
(1)(a)
 is not available;
(iii)
the telepharmacy system maintains records and files quarterly reports as required 
by division rule to assure that patient safety is not compromised; and
(iv)
the arrangement is approved by the division in collaboration with the board.
(c)
Subsection 
(1)(b)
 applies to a pharmacy that is located in a hospital only if the 
hospital is controlled by a local board that owns no more than two hospitals
; and
.
(d)
A supervising pharmacist may not supervise more than two pharmacies 
simultaneously under Subsection 
(1)(b)
.
(2)
Each out-of-state mail service pharmacy shall designate and identify to the division a 
pharmacist holding a current license in good standing issued by the state in which the 
pharmacy is located and who serves as the pharmacist-in-charge for all purposes under 
this chapter.
Section 3. Section 
58-17b-627
 is amended to read:
58-17b-627
. Prescription of drugs or devices by a pharmacist.
(1)
Beginning January 1, 2022, a pharmacist may prescribe a prescription drug or device if:
(a)
prescribing the prescription drug or device is within the scope of the pharmacist's 
training and experience;
(b)
the prescription drug or device is designated by the division by rule under Subsection 
(3)(a)
; and
(c)
the prescription drug or device is not a controlled substance that is included in 
Schedules I, II, III, or IV of:
(i)
Section 
58-37-4
; or
(ii)
the federal Controlled Substances Act, Title II, P.L. 91-513.
(2)
Nothing in this section requires a pharmacist to issue a prescription for a prescription 
drug or device.
(3)
The division shall make rules in accordance with 
Title 63G, Chapter 3, Utah 
Administrative Rulemaking Act
, to:
(a)
designate the prescription drugs or devices that may be prescribed by a pharmacist 
under this section, beginning with prescription drugs or devices that address a public 
health concern that is designated by the Department of Health and Human Services, 
including:
(i)
post-exposure HIV prophylaxis;
(ii)
pre-exposure HIV prophylaxis;
(iii)
self-administered hormonal contraceptives;
(iv)
smoking cessation;
(v)
naloxone;
 and
(vi)
fluoride;
(vii)
vaccines; and
(viii)
epinephrine.
(b)
create guidelines that a pharmacist must follow when prescribing a prescription drug 
or device, including guidelines:
(i)
for notifying the patient's primary care or other health care provider about the 
prescription; and
(ii)
to prevent the over-prescription of drugs or devices including but not limited to 
antibiotics;
(c)
address when a pharmacist should refer the patient to an appropriate health care 
provider or otherwise encourage the patient to seek further medical care; and
(d)
implement the provisions of this section.
(4)
The division shall make rules under Subsection 
(3)
 in collaboration with:
(a)
individuals representing pharmacies and pharmacists;
(b)
individuals representing physicians and advanced practice clinicians; and
(c)
(i)
if the executive director of the Department of Health and Human Services is a 
physician, the executive director of the Department of Health and Human Services;
(ii)
if the executive director of the Department of Health and Human Services is not a 
physician, a deputy director who is a physician in accordance with Subsection 
26B-1-203(4)
; or
(iii)
a designee of the individual described in Section 
26B-1-203
.
(5)
Before November 1 of each year, the division, in consultation with the individuals 
described in Subsection 
(4)
, shall:
(a)
develop recommendations for statutory changes to improve patient access to 
prescribed drugs in the state; and
(b)
report the recommendations developed under Subsection 
(5)(a)
 to the Health and 
Human Services Interim Committee.
Section 4. Section 
58-37c-3
 is amended to read:
58-37c-3
. Definitions.
In addition to the definitions in Section 
58-1-102
, as used in this chapter:
(1)
"Controlled substance precursor" includes a chemical reagent and means any of the 
following:
(a)
Phenyl-2-propanone;
(b)
Methylamine;
(c)
Ethylamine;
(d)
D-lysergic acid;
(e)
Ergotamine and its salts;
(f)
Diethyl malonate;
(g)
Malonic acid;
(h)
Ethyl malonate;
(i)
Barbituric acid;
(j)
Piperidine and its salts;
(k)
N-acetylanthranilic acid and its salts;
(l)
Pyrrolidine;
(m)
Phenylacetic acid and its salts;
(n)
Anthranilic acid and its salts;
(o)
Morpholine;
(p)
Ephedrine;
(q)
Pseudoephedrine;
(r)
Norpseudoephedrine;
(s)
Phenylpropanolamine;
(t)
Benzyl cyanide;
(u)
Ergonovine and its salts;
(v)
3,4-Methylenedioxyphenyl-2-propanone;
(w)
propionic anhydride;
(x)
Insosafrole;
(y)
Safrole;
(z)
Piperonal;
(aa)
N-Methylephedrine;
(bb)
N-ethylephedrine;
(cc)
N-methylpseudoephedrine;
(dd)
N-ethylpseudoephedrine;
(ee)
Hydriotic acid;
(ff)
gamma butyrolactone (GBL), including butyrolactone, 1,2 butanolide, 2-oxanolone, 
tetrahydro-2-furanone, dihydro-2(3H)-furanone, and tetramethylene glycol, but not 
including gamma aminobutric acid (GABA);
(gg)
1,4 butanediol;
(hh)
any salt, isomer, or salt of an isomer of the chemicals listed in Subsections 
(1)(a)
through 
(gg)
;
(ii)
Crystal iodine;
(jj)
Iodine at concentrations greater than 1.5% by weight in a solution or matrix;
(kk)
Red phosphorous, except as provided in Section 
58-37c-19.7
;
(ll)
anhydrous ammonia, except as provided in Section 
58-37c-19.9
;
(mm)
any controlled substance precursor listed under the provisions of the Federal 
Controlled Substances Act which is designated by the director under the emergency 
listing provisions set forth in Section 
58-37c-14
; and
(nn)
any chemical which is designated by the director under the emergency listing 
provisions set forth in Section 
58-37c-14
.
(2)
"Deliver," "delivery," "transfer," or "furnish" means the actual, constructive, or 
attempted transfer of a controlled substance precursor.
(3)
"Matrix" means something, as a substance, in which something else originates, 
develops, or is contained.
(4)
"Person" means any individual, group of individuals, proprietorship, partnership, joint 
venture, corporation, or organization of any type or kind.
(5)
"Practitioner" means a physician, physician assistant, dentist, podiatric physician, 
veterinarian, pharmacist, scientific investigator, pharmacy, hospital, pharmaceutical 
manufacturer, or other person licensed, registered, or otherwise permitted to distribute, 
dispense, conduct research with respect to, administer, or use in teaching or chemical 
analysis a controlled substance in the course of professional practice or research in this 
state.
(6)
(a)
"Regulated distributor" means a person within the state who provides, sells, 
furnishes, transfers, or otherwise supplies a listed controlled substance precursor 
chemical in a regulated transaction.
(b)
"Regulated distributor" does not include any person excluded from regulation under 
this chapter.
(7)
(a)
"Regulated purchaser" means any person within the state who receives a listed 
controlled substance precursor chemical in a regulated transaction.
(b)
"Regulated purchaser" does not include any person excluded from regulation under 
this chapter.
(8)
"Regulated transaction" means any actual, constructive or attempted:
(a)
transfer, distribution, delivery, or furnishing by a person within the state to another 
person within or outside of the state of a threshold amount of a listed precursor 
chemical; or
(b)
purchase or acquisition by any means by a person within the state from another 
person within or outside the state of a threshold amount of a listed precursor chemical.
(9)
"Retail distributor" means a grocery store, general merchandise store, drug store, 
online 
retailer, 
or other entity or person whose activities as a distributor are limited almost 
exclusively to sales for personal use:
(a)
in both number of sales and volume of sales; and
(b)
either 
directly to walk-in customers or in face-to-face transactions by direct sales
by 
direct in-store sales or by online sales fulfilled by 
delivery in-person 
or curbside 
pickup
.
(10)
"Threshold amount of a listed precursor chemical" means any amount of a controlled 
substance precursor or a specified amount of a controlled substance precursor in a 
matrix; however, the division may exempt from the provisions of this chapter a specific 
controlled substance precursor in a specific amount and in certain types of transactions 
which provisions for exemption shall be defined by the division by rule adopted 
pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
(11)
"Unlawful conduct" as defined in Section 
58-1-501
 includes knowingly and 
intentionally:
(a)
engaging in a regulated transaction without first being appropriately licensed or 
exempted from licensure under this chapter;
(b)
acting as a regulated distributor and selling, transferring, or in any other way 
conveying a controlled substance precursor to a person within the state who is not 
appropriately licensed or exempted from licensure as a regulated purchaser, or 
selling, transferring, or otherwise conveying a controlled substance precursor to a 
person outside of the state and failing to report the transaction as required;
(c)
acting as a regulated purchaser and purchasing or in any other way obtaining a 
controlled substance precursor from a person within the state who is not a licensed 
regulated distributor, or purchasing or otherwise obtaining a controlled substance 
precursor from a person outside of the state and failing to report the transaction as 
required;
(d)
engaging in a regulated transaction and failing to submit reports and keep required 
records of inventories required under the provisions of this chapter or rules adopted 
pursuant to this chapter;
(e)
making any false statement in any application for license, in any record to be kept, or 
on any report submitted as required under this chapter;
(f)
with the intent of causing the evasion of the recordkeeping or reporting requirements 
of this chapter and rules related to this chapter, receiving or distributing any listed 
controlled substance precursor chemical in any manner designed so that the making 
of records or filing of reports required under this chapter is not required;
(g)
failing to take immediate steps to comply with licensure, reporting, or recordkeeping 
requirements of this chapter because of lack of knowledge of those requirements, 
upon becoming informed of the requirements;
(h)
presenting false or fraudulent identification where or when receiving or purchasing a 
listed controlled substance precursor chemical;
(i)
creating a chemical mixture for the purpose of evading any licensure, reporting or 
recordkeeping requirement of this chapter or rules related to this chapter, or receiving 
a chemical mixture created for that purpose;
(j)
if the person is at least 18 years 
of ag
e
old
, employing, hiring, using, persuading, 
inducing, enticing, or coercing another person under 18 years 
of ag
e
old
to violate 
any provision of this chapter, or assisting in avoiding detection or apprehension for 
any violation of this chapter by any federal, state, or local law enforcement official; 
and
(k)
obtaining or attempting to obtain or to possess any controlled substance precursor or 
any combination of controlled substance precursors knowing or having a reasonable 
cause to believe that the controlled substance precursor is intended to be used in the 
unlawful manufacture of any controlled substance.
(12)
"Unprofessional conduct" as defined in Section 
58-1-102
 and as may be further 
defined by rule includes the following:
(a)
violation of any provision of this chapter, the Controlled Substance Act of this state 
or any other state, or the 
Federal
f
e
d
e
r
a
l
 Controlled Substance Act; and
(b)
refusing to allow agents or representatives of the division or authorized law 
enforcement personnel to inspect inventories or controlled substance precursors or 
records or reports relating to purchases and sales or distribution of controlled 
substance precursors as such records and reports are required under this chapter.
Section 5. Section 
58-37c-22
 is enacted to read:
58-37c-22
. Online sales of pseudoephedrine -- Electronic tracking system.
(1)
As used in this section:
(a)
"Electronic tracking system" means the real-time, stop-sale electronic sales tracking 
system described in Subsection 
(2)
.
(b)
"Product" means the same as that term is defined in Section 
58-37c-20.5
.
(c)
"Stop-sale alert" means an alert an electronic tracking system sends to a retail 
distributor to stop the sale of a product if the sale would violate Section 
58-37c-20.5
or any other law that prohibits the sale of a product.
(2)
Except as provided in Subsection 
(4)
, the division shall, in accordance with Title 63G, 
Chapter 3, Utah Administrative 
Rulemaking Act, make rules, in consultation with the 
Board of Pharmacy, to:
(a)
approve and implement a real-time, stop-sale electronic sales tracking system to 
monitor the nonprescription sale, including the online sale, of products by a retail 
distributor; and
(b)
establish procedures for the online sale of a product.
(3)
The electronic tracking system shall:
(a)
be capable of:
(i)
allowing a retail distributor or purchaser of a product to electronically submit 
information to the electronic tracking system before the sale of a product;
(ii)
determining whether the sale of the product would violate Section 
58-37c-20.5
 or 
any other law that prohibits the sale of a product;
(iii)
sending a stop-sale alert;
(iv)
allowing a retail distributor to override a stop-sale alert;
(v)
logging each instance of a stop-sale alert override; and
(vi)
allowing law enforcement agencies to access the electronic tracking system's 
records of a sale or attempted sale of a product; and
(b)
be free of charge for use by retail distributors and law enforcement agencies.
(4)
(a)
If a real-time, stop-sale electronic sales tracking system is not available to the 
state without charge for accessing the system to the state or retailers, the division is 
not required to approve and implement an electronic tracking system.
(b)
If the division does not approve and implement an electronic tracking system, the 
online sale of a product is prohibited.
(5)
After the division approves an electronic tracking system, the division, in coordination 
with the Board of Pharmacy, shall notify each retail distributor of the approved 
electronic tracking system.
(6)
A retail distributor shall obtain all required information from the purchaser of a product 
and submit the information to the electronic tracking system before completing a sale as 
described in this section.
(7)
A retail distributor that participates in the electronic tracking system may not complete a 
sale for which the electronic tracking system sends a stop-sale alert.
(8)
Records a retail distributor submits to the electronic tracking system are for the 
confidential use of the retail distributor, except that the retail distributor shall:
(a)
produce the records in court when required by law;
(b)
make the records available for inspection by the division and the board; and
(c)
make the records available to:
(i)
the Criminal Investigations and Technical Services Division of the Department of 
Public Safety created in Section 
53-10-103
, for the purpose of enforcing this 
chapter; and
(ii)
federal law enforcement officers.
(9)
The rules the division makes to implement the electronic tracking system shall:
(a)
establish the minimum requirements for the electronic tracking system;
(b)
establish regulations for use of, and access to, the electronic tracking system;
(c)
establish exceptions to the prohibition in Subsection 
(7)
, including:
(i)
if a pharmacist or an employee of a retail distributor has a reasonable fear of 
imminent bodily harm if the sale is not completed; and
(ii)
if a retail distributor experiences a mechanical or electronic failure of the 
electronic tracking system; and
(d)
require a retail distributor to submit the following to the electronic tracking system 
for each online sale of a product:
(i)
the purchaser's name and address;
(ii)
the purchaser's signature, either on a written form or stored electronically in the 
electronic tracking system, attesting to the validity of all information the purchaser 
provides in the electronic tracking system;
(iii)
the type of identification the purchaser presented in accordance with Section 
58-37c-20.5
;
(iv)
the identification number and name of the government entity that issued the 
identification described in Subsection 
(9)(d)(iii)
;
(v)
the date and time of the sale of the product; and
(vi)
the name and quantity of the product sold.
(10)
A retail distributor that participates in the electronic tracking system is not liable for 
civil damages that are the result of:
(a)
any act or omission in carrying out the requirements of this section, rules the division 
makes in accordance with this section, or Section 
58-37c-20.5
, except for an act or 
omission that constitutes gross negligence or willful misconduct; and
(b)
a data breach that was proximately caused by the electronic tracking system's failure 
to take reasonable care through the use of industry standard levels of encryption to 
guard against unauthorized access to account information that is in the possession or 
control of the electronic tracking system.
Section 6. 
Effective Date.
This bill takes effect on 
May 6, 2026
.
3-10-26 2:34 PM